Title IX of the reauthorization would require drug manufacturers to notify the FDA in advance of an anticipated disruption in the production of key drugs, enabling the agency respond in a timely fashion. Title IX would also authorize the Secretary of the Department of Health and Human Services to process expedited inspections of drug applications and manufacturing facilities in an effort to help alleviate pending drug shortages.
The House version of the PDUFA will now be reconciled with the Senate, which approved the Act on Monday.
Related Articles on Anesthesia:
5 Issues in the CRNA Supervision Debate: Anesthesiologists Weigh in
Electronic Reminders Improve Accuracy of Anesthesia Billing
ASA to Congress: Consider Anesthesia-Led Efforts to Lower Costs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
